95 Oral misoprostol or vaginal dinoprostone for labor induction? A randomized controlled trial
Patrick Dällenbach+3 more
openalex +1 more source
Investigating differences in gene expression in term laboring myometrium compared to preterm laboring and failed post-date induction myometrium [PDF]
Kimberly Pilkinton+3 more
openalex +1 more source
scCompass: An Integrated Multi‐Species scRNA‐seq Database for AI‐Ready
scCompass integrates and standardizes transcriptomic data from ≈105 million single cells across 13 species, enabling the identification of stable expression genes and organ‐specific expression genes in humans and mice. It provides scalable datasets for AI model training, pretrained model checkpoints, and user‐friendly platforms for data sharing ...
Pengfei Wang+29 more
wiley +1 more source
440 Lower dose vaginal and oral misoprostol in labor induction—RCT
David C. Young+3 more
openalex +1 more source
Indicated induction of labor at term with an unfavorable cervix: Immune system gene polymorphism associations [PDF]
Daniel Skupski+3 more
openalex +1 more source
FABP4 as a Mediator of Lipid Metabolism and Pregnant Uterine Dysfunction in Obesity
Obesity during late pregnancy contributes to uterine smooth muscle dysfunction, but the underlying mechanisms are unclear. This study identifies fatty acid binding protein 4 (FABP4) as a key player in the process, mediating excessive fatty acid uptake, lipid accumulation, and mitochondrial dysfunction in myometrial cells. FABP4 could be a novel uterine
Xuan Li+11 more
wiley +1 more source
437 Oral misoprostol labor induction in patients with a favorable cervix
Tina Delaney+4 more
openalex +1 more source
Mode of delivery in pregnant women with hypertensive disorders and unfavorable cervix following induction of labor with vaginal application of prostaglandin E2 [PDF]
Avi Ben‐Haroush+5 more
openalex +1 more source
The study identified sortilin as a promising LTR, enabling targeted degradation of oncogenic proteins through an mRNA‐encoded MedTAC strategy. In a mouse model, MedTACPTK7 reduced PTK7 by up to 80%, extended survival, and showed excellent pharmacokinetics without toxicity, providing a scalable platform for targeted therapies.
Xin Chang+8 more
wiley +1 more source